Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer In Two-Front Battle To Defend Product-Line Amid Merger Talks

Executive Summary

Speculation about potential mergers involving Monsanto may raise the stakes for Pfizer in its bid to acquire Warner-Lambert.

You may also be interested in...



Pfizer Expects Menstrually-Associated Migraine Claim For Relpax

Pfizer expects Relpax (eletriptan) to be the first triptan to receive a labeling claim for relief of menstrually-associated migraines.

Pfizer Expects Menstrually-Associated Migraine Claim For Relpax

Pfizer expects Relpax (eletriptan) to be the first triptan to receive a labeling claim for relief of menstrually-associated migraines.

Warner-Lambert And AHP Plan Protonix Copromotion Agreement

Warner-Lambert and American Home Products intend to complete a co-promotion agreement for AHP's proton pump inhibitor Protonix.

Related Content

UsernamePublicRestriction

Register

PS035173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel